# The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer

> **NCT04416854** · PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 627 (estimated)

## Conditions studied

- Metastatic Colon Cancer
- Surgery

## Interventions

- **PROCEDURE:** resection of primary tumor
- **DRUG:** XELOX
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT04416854
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 627 (ESTIMATED)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04416854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04416854, "The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04416854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*